Identification of surface-associated antigens for tumor diagnosis and therapy
An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.
1. A method of detecting and treating a head neck cancer which is characterized by expressing a tumor-associated antigen having the amino acid sequence shown in SEQ ID NO:4, which method comprises:
(A) detecting or quantifying in a biological sample isolated from a patient said tumor-associated antigen by:
(i) isolating a biological sample from tissue in the head or neck region of a patient suspected of having head neck cancer,
(ii) contacting the biological sample with a first antibody which binds specifically to the tumor-associated antigen,
(iii) detecting or quantifying the formation of a complex between the first antibody and the tumor-associated antigen,
(iv) comparing the presence or quantity of the complex in the biological sample from the patient to the presence or quantity of the complex in a comparable normal biological sample that also has been contacted with the antibody,
(v) concluding from an increase in the amount of the complex in the biological sample from the patient relative to the normal biological sample that the patient is affected by a head neck cancer, and
(B) treating the so-affected patient with a second antibody which specifically binds to an extracellular portion of said tumor-associated antigen and which is coupled to a therapeutic agent.
2. The method of claim 1 , wherein the biological sample comprises body fluid, body tissue, or a combination thereof.
3. The method of claim 1 , wherein the biological sample comprises ear, nose or throat tissue.
4. The method of claim 1 , wherein the first antibody is labeled with a detectable marker.
5. The method of claim 4 , wherein the detectable marker is a radioactive marker or an enzymic marker.
6. The method of claim 1 , wherein the first and second antibodies are monoclonal antibodies.
7. The method of claim 4 , wherein the detectable marker is selected from the group consisting of barium sulfate, iocetamic acid, iopanoic acid, calcium ipodate, sodium diatrizoate, meglumine diatrizoate, metrizamide, and sodium tyropanoate.
8. The method of claim 5 , wherein the detectable marker is a radioactive marker selected from the group consisting of fluorine-18, carbon-11, iodine-123, technetium-99, iodine-131, and indium-111.
9. The method of claim 1 , wherein the therapeutic agent is an anticancer agent, a radioactive iodine-labeled compound, a toxin, a cytostatic drug, or a cytolytic drug.
10. The method of claim 1 , wherein the therapeutic agent is an anticancer agent selected from the group consisting of aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabidine, dacarbazine, dactinomycin, daunorubin, doxorubicin, taxol, etoposide, fluorouracil, interferon-α, lomustine, mercaptopurine, methoxtrexate, mitotane, procarbazine HCl, thioguanine, vinblastine sulfate, and vincristine sulfate.
11. The method of claim 9 , wherein the therapeutic agent is a toxin selected from the group consisting of pokeweed antiviral protein, cholera toxin, pertussis toxin, ricin, gelonin, abrin, diptheria exotoxin and Pseudomonas exotoxin.